Goldstein Advisors LLC Has $128,000 Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Goldstein Advisors LLC increased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 24.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,800 shares of the company’s stock after buying an additional 7,375 shares during the quarter. Goldstein Advisors LLC’s holdings in Xeris Biopharma were worth $128,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in XERS. Walleye Capital LLC acquired a new stake in shares of Xeris Biopharma in the 3rd quarter valued at approximately $3,197,000. Renaissance Technologies LLC boosted its holdings in shares of Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after buying an additional 342,300 shares during the last quarter. Barclays PLC boosted its holdings in shares of Xeris Biopharma by 87.8% in the 3rd quarter. Barclays PLC now owns 324,472 shares of the company’s stock valued at $925,000 after buying an additional 151,685 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock valued at $9,502,000 after buying an additional 93,091 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Xeris Biopharma in the 3rd quarter valued at approximately $237,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

XERS opened at $3.29 on Thursday. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $3.87. The stock’s fifty day simple moving average is $3.34 and its 200 day simple moving average is $2.97.

Wall Street Analyst Weigh In

XERS has been the subject of several recent analyst reports. Piper Sandler downgraded Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Monday, November 11th. HC Wainwright increased their price target on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.